Biomarkers.

Area of Science:

• Neuroscience
• Biomarkers
• Clinical Trials

Background:

• Alzheimer's Disease (AD) and agitation are significant challenges in patient care.
• The S-CitAD trial investigated escitalopram for agitation in AD, but showed no significant benefit.
• Variability in AD pathology stages may explain the lack of treatment efficacy.

Purpose of the Study:

• To investigate the association between baseline blood biomarkers and agitation severity, cognitive status, and treatment response in AD patients.
• To explore the role of biomarkers like pTau217, GFAP, NfL, Abeta40, and Abeta42 in predicting agitation and cognitive decline.

Main Methods:

• Examined associations between baseline blood biomarkers (pTau217, GFAP, NfL, Abeta40, Abeta42) and clinical measures (agitation, MMSE).
• Utilized SIMOA N4PE assays and Alzpath-pTau217 SIMOA on Quanterix HD-X for biomarker quantification.
• Analyzed data from 173 participants in the S-CitAD randomized controlled trial.

Main Results:

• Baseline pTau217 levels confirmed significant amyloid pathology in 94% of participants.
• Higher baseline pTau217 predicted increased agitation severity at weeks 6 and 12.
• Higher baseline GFAP and pTau217 levels were associated with lower baseline MMSE scores.

Conclusions:

• Baseline pTau217 is a reliable indicator of AD amyloid pathology.
• Elevated pTau217 predicts poorer cognitive function and increased agitation in AD patients.
• Biomarker levels, particularly pTau217, are crucial for understanding treatment response and disease progression in AD.